High throughput screening identifies modulators of histone deacetylase inhibitors

BMC Genomics

Volumn 15, Issue 1, 2014, Pages

  Gaupel, Ann Christin ^a   Begley, Thomas ^a,b   Tenniswood, Martin ^a  

^a STATE UNIVERSITY OF NEW YORK   (United States)

^b SUNY POLYTECHNIC INSTITUTE   (United States)

Author keywords

CG 1521; Chromatin remodeling; Gcn5; Histone acetyltransferase; Histone deacetylase inhibitor; SAGA complex; Transcription; Yeast deletion library screen

Indexed keywords

7 PHENYL 2,4,6 HEPTATRIENOIC HYDROXAMIC ACID; ANTINEOPLASTIC AGENT; CG 1521; HISTONE ACETYLTRANSFERASE GCN5; HISTONE DEACETYLASE INHIBITOR; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR SAGA; TRANSFER RNA; UNCLASSIFIED DRUG; 7-PHENYL-2,4,6-HEPTATRIENOYLHYDROXAMIC ACID; HISTONE ACETYLTRANSFERASE; HISTONE DEACETYLASE; HYDROXAMIC ACID; SACCHAROMYCES CEREVISIAE PROTEIN;

ACIDIFICATION; ARTICLE; CATALYSIS; CELL CYCLE; CELL DEATH; CELL VACUOLE; CHEMOSENSITIVITY; CHROMATIN ASSEMBLY AND DISASSEMBLY; CONTROLLED STUDY; DNA MODIFICATION; DRUG RESISTANCE; ENZYME ACTIVITY; FUNGAL GENE; FUNGAL STRAIN; FUNGUS GROWTH; GENE DELETION; HAPLOIDY; HIGH THROUGHPUT SCREENING; NONHUMAN; PROTEIN EXPRESSION; SACCHAROMYCES CEREVISIAE; STRAIN DIFFERENCE; TRANSCRIPTION REGULATION; ANTIFUNGAL RESISTANCE; BIOLOGY; DRUG DEVELOPMENT; DRUG EFFECTS; GENETIC TRANSCRIPTION; GENETICS; GENOTYPE; METABOLISM; MICROBIAL SENSITIVITY TEST; MUTATION; PHENOTYPE;

SACCHAROMYCES CEREVISIAE;

CELL CYCLE; CELL DEATH; CHROMATIN ASSEMBLY AND DISASSEMBLY; COMPUTATIONAL BIOLOGY; DRUG DISCOVERY; DRUG RESISTANCE, FUNGAL; GENOTYPE; HIGH-THROUGHPUT SCREENING ASSAYS; HISTONE ACETYLTRANSFERASES; HISTONE DEACETYLASE INHIBITORS; HISTONE DEACETYLASES; HYDROXAMIC ACIDS; MICROBIAL SENSITIVITY TESTS; MUTATION; PHENOTYPE; SACCHAROMYCES CEREVISIAE; SACCHAROMYCES CEREVISIAE PROTEINS; TRANSCRIPTION, GENETIC;

EID: 84902930515     PISSN: None     EISSN: 14712164     Source Type: Journal    
DOI: 10.1186/1471-2164-15-528     Document Type: Article

References (91)

1. Fraga MF, Ballestar E, Villar-Garea A, Boix-Chornet M, Espada J, Schotta G, Bonaldi T, Haydon C, Ropero S, Petrie K, Iyer NG, Pérez-Rosado A, Calvo E, Lopez JA, Cano A, Calasanz MJ, Colomer D, Piris MA, Ahn N, Imhof A, Caldas C, Jenuwein T, Esteller M. Loss of acetylation at Lys16 and trimethylation at Lys20 of histone H4 is a common hallmark of human cancer. Nat Genet 2005, 37:391-400.
2. Seligson DB, Horvath S, McBrian MA, Mah V, Yu H, Tze S, Wang Q, Chia D, Goodglick L, Kurdistani SK. Global levels of histone modifications predict prognosis in different cancers. Am J Pathol 2009, 174:1619-1628.
3. Seligson DB, Horvath S, Shi T, Yu H, Tze S, Grunstein M, Kurdistani SK. Global histone modification patterns predict risk of prostate cancer recurrence. Nature 2005, 435:1262-1266.
4. Wang W, Xu L, Kong J, Fan H, Yang P. Quantitative research of histone H3 acetylation levels of human hepatocellular carcinoma cells. Bioanalysis 2013, 5:327-339.
5. Witt O, Deubzer HE, Milde T, Oehme I. HDAC family: what are the cancer relevant targets?. Cancer Lett 2009, 277:8-21.
6. Moreno DA, Scrideli CA, Cortez MAA, de Paula Queiroz R, Valera ET, da Silva Silveira V, Yunes JA, Brandalise SR, Tone LG. Differential expression of HDAC3, HDAC7 and HDAC9 is associated with prognosis and survival in childhood acute lymphoblastic leukaemia. Brit J Haematol 2010, 150:665-673.
7. Dokmanovic M, Clarke C, Marks PA. Histone deacetylase inhibitors: overview and perspectives. Mol Cancer Res 2007, 5:981-989.
8. Frew AJ, Johnstone RW, Bolden JE. Enhancing the apoptotic and therapeutic effects of HDAC inhibitors. Cancer Lett 2009, 280:125-133.
9. Dokmanovic M, Marks PA. Prospects: histone deacetylase inhibitors. J Cell Biochem 2005, 96:293-304.
10. Ungerstedt JS, Sowa Y, Xu W-S, Shao Y, Dokmanovic M, Perez G, Ngo L, Holmgren A, Jiang X, Marks PA. Role of thioredoxin in the response of normal and transformed cells to histone deacetylase inhibitors. Proc Natl Acad Sci U S A 2005, 102:673-678.
11. Zhang C, Richon V, Ni X, Talpur R, Duvic M. Selective induction of apoptosis by histone deacetylase inhibitor SAHA in cutaneous T-cell lymphoma cells: relevance to mechanism of therapeutic action. J Invest Dermatol 2005, 125:1045-1052.
12. Borbone E, Berlingieri MT, De Bellis F, Nebbioso A, Chiappetta G, Mai A, Altucci L, Fusco A. Histone deacetylase inhibitors induce thyroid cancer-specific apoptosis through proteasome-dependent inhibition of TRAIL degradation. Oncogene 2010, 29:105-116.
13. Marks PA, Breslow R. Dimethyl sulfoxide to vorinostat: development of this histone deacetylase inhibitor as an anticancer drug. Nat Biotechnol 2007, 25:84-90.
14. VanderMolen KM, McCulloch W, Pearce CJ, Oberlies NH. Romidepsin (Istodax, NSC 630176, FR901228, FK228, depsipeptide): a natural product recently approved for cutaneous T-cell lymphoma. J Antibiot 2011, 64:525-531.
15. Roy S, Packman K, Jeffrey R, Tenniswood M. Histone deacetylase inhibitors differentially stabilize acetylated p53 and induce cell cycle arrest or apoptosis in prostate cancer cells. Cell Death Differ 2005, 12:482-491.
16. Knutson AKA, Welsh J, Taylor T, Roy S, Wang W-LW, Tenniswood M. Comparative effects of histone deacetylase inhibitors on p53 target gene expression, cell cycle and apoptosis in MCF-7 breast cancer cells. Oncol Rep 2012, 27:849-853.
17. Chatterjee N, Wang W-LW, Conklin T, Chittur S, Tenniswood M. Histone deacetylase inhibitors modulate miRNA and mRNA expression, block metaphase, and induce apoptosis in inflammatory breast cancer cells. Cancer Biol Ther 2013, 14:658-671.
18. Roy S, Jeffrey R, Tenniswood M. Array-based analysis of the effects of trichostatin A and CG-1521 on cell cycle and cell death in LNCaP prostate cancer cells. Mol Cancer Ther 2008, 7:1931-1939.
19. Roy S, Tenniswood M. Site-specific acetylation of p53 directs selective transcription complex assembly. J Biol Chem 2007, 7:4765-4771.
20. Ito T, Chiba T, Ozawa R, Yoshida M, Hattori M, Sakaki Y. A comprehensive two-hybrid analysis to explore the yeast protein interactome. Proc Natl Acad Sci U S A 2001, 98:4569-4574.
21. Ito T, Tashiro K, Muta S, Ozawa R, Chiba T, Nishizawa M, Yamamoto K, Kuhara S, Sakaki Y. Toward a protein-protein interaction map of the budding yeast: a comprehensive system to examine two-hybrid interactions in all possible combinations between the yeast proteins. Proc Natl Acad Sci U S A 2000, 97:1143-1147.
22. Tong AH, Evangelista M, Parsons AB, Xu H, Bader GD, Pagé N, Robinson M, Raghibizadeh S, Hogue CW, Bussey H, Andrews B, Tyers M, Boone C. Systematic genetic analysis with ordered arrays of yeast deletion mutants. Science 2001, 294:2364-2368.
23. Hughes TR, Marton MJ, Jones AR, Roberts CJ, Stoughton R, Armour CD, Bennett HA, Coffey E, Dai H, He YD, Kidd MJ, King AM, Meyer MR, Slade D, Lum PY, Stepaniants SB, Shoemaker DD, Gachotte D, Chakraburtty K, Simon J, Bard M, Friend SH. Functional discovery via a compendium of expression profiles. Cell 2000, 102:109-126.
24. Gregoretti IV, Lee Y-M, Goodson HV. Molecular evolution of the histone deacetylase family: functional implications of phylogenetic analysis. J Mol Biol 2004, 338:17-31.
25. Langer MR, Fry CJ, Peterson CL, Denu JM. Modulating acetyl-CoA binding in the GCN5 family of histone acetyltransferases. J Biol Chem 2002, 277:27337-27344.
26. Doyon Y, Côté J. The highly conserved and multifunctional NuA4 HAT complex. Curr Opin Genet Dev 2004, 14:147-154.
27. Ramachandran S, Vogel L, Strahl BD, Dokholyan NV. Thermodynamic stability of histone H3 is a necessary but not sufficient driving force for its evolutionary conservation. PLoS Comput Biol 2011, 7:e1001042.
28. Huang DW, Sherman BT, Lempicki RA. Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nat Prot 2009, 4:44-57.
29. Jantzen SG, Sutherland BJ, Minkley DR, Koop BF. GO trimming: systematically reducing redundancy in large gene ontology datasets. BMC Res Notes 2011, 4:267.
30. Lee KK, Sardiu ME, Swanson SK, Gilmore JM, Torok M, Grant P, Florens L, Workman JL, Washburn MP. Combinatorial depletion analysis to assemble the network architecture of the SAGA and ADA chromatin remodeling complexes. Mol Syst Biol 2011, 7:503.
31. Langer MR, Tanner KG, Denu JM. Mutational analysis of conserved residues in the GCN5 family of histone acetyltransferases. J Biol Chem 2001, 276:31321-31331.
32. Orpinell M, Fournier M, Riss A, Nagy Z, Krebs AR, Frontini M, Tora L. The ATAC acetyl transferase complex controls mitotic progression by targeting non-histone substrates. EMBO J 2010, 29:2381-2394.
33. Vernarecci S, Ornaghi P, Bâgu A, Cundari E, Ballario P, Filetici P. Gcn5p plays an important role in centromere kinetochore function in budding yeast. Mol Cell Biol 2008, 28:988-996.
34. Giannini G, Cabri W, Fattorusso C, Rodriquez M. Histone deacetylase inhibitors in the treatment of cancer: overview and perspectives. Future Med Chem 2012, 4:1439-1460.
35. Lane AA, Chabner BA. Histone deacetylase inhibitors in cancer therapy. J Clin Oncol 2009, 27:5459-5468.
36. Schrump DS. Cytotoxicity mediated by histone deacetylase inhibitors in cancer cells: mechanisms and potential clinical implications. Clin Cancer Res 2009, 15:3947-3957.
37. Choudhary C, Kumar C, Gnad F, Nielsen ML, Rehman M, Walther TC, Olsen JV, Mann M. Lysine acetylation targets protein complexes and co-regulates major cellular functions. Science 2009, 325:834-840.
38. Ekwall K, Olsson T, Turner BM, Cranston G, Allshire RC. Transient inhibition of histone deacetylation alters the structural and functional imprint at fission yeast centromeres. Cell 1997, 91:1021-1032.
39. Kimata Y, Matsuyama A, Nagao K, Furuya K, Obuse C, Yoshida M, Yanagida M. Diminishing HDACs by drugs or mutations promotes normal or abnormal sister chromatid separation by affecting APC/C and adherin. J Cell Sci 2008, 121:1107-1118.
40. Cimini D, Mattiuzzo M, Torosantucci L, Degrassi F. Histone Hyperacetylation in mitosis prevents sister chromatid separation and produces chromosome segregation defects. Mol Biol Cell 2003, 14:3821-3833.
41. Shin HJ, Baek KH, Jeon AH, Kim SJ, Jang KL, Sung YC, Kim CM, Lee CW. Inhibition of histone deacetylase activity increases chromosomal instability by the aberrant regulation of mitotic checkpoint activation. Oncogene 2003, 22:3853-3858.
42. Peng W, Togawa C, Zhang K, Kurdistani SK. Regulators of cellular levels of histone acetylation in Saccharomyces cerevisiae. Genetics 2008, 179:277-289.
43. Ingvarsdottir K, Krogan NJ, Emre NCT, Wyce A, Thompson NJ, Emili A, Hughes TR, Greenblatt JF, Berger SL. H2B ubiquitin protease Ubp8 and Sgf11 constitute a discrete functional module within the Saccharomyces cerevisiae SAGA complex. Mol Cell Biol 2005, 25:1162-1172.
44. Bhaumik SR. Distinct regulatory mechanisms of eukaryotic transcriptional activation by SAGA and TFIID. Biochim Biophys Acta 1809, 2011:97-108.
45. Köhler A, Schneider M, Cabal GG, Nehrbass U, Hurt E. Yeast Ataxin-7 links histone deubiquitination with gene gating and mRNA export. Nat Cell Biol 2008, 10:707-715.
46. Shukla A, Bajwa P, Bhaumik SR. SAGA-associated Sgf73p facilitates formation of the preinitiation complex assembly at the promoters either in a HAT-dependent or independent manner in vivo. Nucleic Acids Rres 2006, 34:6225-6232.
47. Jia Y, Rothermel B, Thornton J, Butow RA. A basic helix-loop-helix-leucine zipper transcription complex in yeast functions in a signaling pathway from mitochondria to the nucleus. Mol Cell Biol 1997, 17:1110-1117.
48. Liao X, Butow RRA. RTG1 and RTG2: two yeast genes required for a novel path of communication from mitochondria to the nucleus. Cell 1993, 72:61-71.
49. Rothermel BA, Shyjan AW, Etheredge JL, Butow RA. Transactivation by Rtg1p, a basic helix-loop-helix protein that functions in communication between mitochondria and the nucleus in yeast. J Biol Chem 1995, 270:29476-29482.
50. Liu Z, Sekito T, Epstein CB, Butow RA. RTG-dependent mitochondria to nucleus signaling is negatively regulated by the seven WD-repeat protein Lst8p. EMBO J 2001, 20:7209-7219.
51. Liu Z, Sekito T, Spírek M, Thornton J, Butow RA. Retrograde signaling is regulated by the dynamic interaction between Rtg2p and Mks1p. Mol Cell 2003, 12:401-411.
52. Crespo JL, Powers T, Fowler B, Hall MN. The TOR-controlled transcription activators GLN3, RTG1, and RTG3 are regulated in response to intracellular levels of glutamine. Proc Natl Acad Sci U S A 2002, 99:6784-6789.
53. Pray-Grant MG, Schieltz D, McMahon SJ, Wood JM, Kennedy EL, Cook RG, Workman JL, Yates JR, Grant PA. The novel SLIK histone acetyltransferase complex functions in the yeast retrograde response pathway. Mol Cell Biol 2002, 22:8774-8786.
54. Lee TI, Causton HC, Holstege FC, Shen WC, Hannett N, Jennings EG, Winston F, Green MR, Young RA. Redundant roles for the TFIID and SAGA complexes in global transcription. Nature 2000, 405:701-704.
55. Bu P, Evrard YA, Lozano G, Dent SYR. Loss of Gcn5 acetyltransferase activity leads to neural tube closure defects and exencephaly in mouse embryos. Mol Cell Biol 2007, 27:3405-3416.
56. Cherry JM, Hong EL, Amundsen C, Balakrishnan R, Binkley G, Chan ET, Christie KR, Costanzo MC, Dwight SS, Engel SR, Fisk DG, Hirschman JE, Hitz BC, Karra K, Krieger CJ, Miyasato SR, Nash RS, Park J, Skrzypek MS, Simison M, Weng S, Wong ED. Saccharomyces genome database: the genomics resource of budding yeast. Nucleic Acids Res 2011, 40(Database issue):D700-D705.
57. Lin YY, Qi Y, Lu JY, Pan X, Yuan DS, Zhao Y, Bader JS, Boeke JD. A comprehensive synthetic genetic interaction network governing yeast histone acetylation and deacetylation. Genes Dev 2008, 22:2062-2074.
58. Collins SR, Miller KM, Maas NL, Roguev A, Fillingham J, Chu CS, Schuldiner M, Gebbia M, Recht J, Shales M, Ding H, Xu H, Han J, Ingvarsdottir K, Cheng B, Andrews B, Boone C, Berger SL, Hieter P, Zhang Z, Brown GW, Ingles CJ, Emili A, Allis CD, Toczyski DP, Weissman JS, Greenblatt JF, Krogan NJ. Functional dissection of protein complexes involved in yeast chromosome biology using a genetic interaction map. Nature 2007, 446:806-810.
59. Costanzo M, Baryshnikova A, Bellay J, Kim Y, Spear ED, Sevier CS, Ding H, Koh JL, Toufighi K, Mostafavi S, Prinz J, St Onge RP, VanderSluis B, Makhnevych T, Vizeacoumar FJ, Alizadeh S, Bahr S, Brost RL, Chen Y, Cokol M, Deshpande R, Li Z, Lin ZY, Liang W, Marback M, Paw J, San Luis BJ, Shuteriqi E, Tong AH, van Dyk N, et al. The genetic landscape of a cell. Science 2010, 327:425-431.
60. Spedale G, Timmers HTM, Pijnappel WWMP. ATAC-king the complexity of SAGA during evolution. Genes Dev 2012, 26:527-541.
61. Nagy Z, Tora L. Distinct GCN5/PCAF-containing complexes function as co-activators and are involved in transcription factor and global histone acetylation. Oncogene 2007, 26:5341-5357.
62. McMahon SB, Van Buskirk HA, Dugan KA, Copeland TD, Cole MD. The novel ATM-related protein TRRAP is an essential cofactor for the c-Myc and E2F oncoproteins. Cell 1998, 94:363-374.
63. Frank SR, Schroeder M, Fernandez P, Taubert S, Amati B. Binding of c-Myc to chromatin mediates mitogen-induced acetylation of histone H4 and gene activation. Genes & Dev 2001, 15:2069-2082.
64. Martínez-Cerdeño V, Lemen JM, Chan V, Wey A, Lin W, Dent SR, Knoepfler PS. N-Myc and GCN5 regulate significantly overlapping transcriptional programs in neural stem cells. PLoS One 2012, 7:e39456.
65. Spotts G, Patel S, Xiao Q, Hann S. Identification of downstream-initiated c-Myc proteins which are dominant-negative inhibitors of transactivation by full-length c-Myc proteins. Mol Cell Biol 1997, 17:1459-1468.
66. McMahon S, Wood M, Cole M. The essential cofactor TRRAP recruits the histone acetyltransferase hGCN5 to c-Myc. Mol Cell Biol 2000, 20:556-562.
67. Liu X, Tesfai J, Evrard YA, Dent SYR, Martinez E. c-Myc transformation domain recruits the human STAGA complex and requires TRRAP and GCN5 acetylase activity for transcription activation. J Biol Chem 2003, 278:20405-20412.
68. Knoepfler PS, Zhang X-Y, Cheng PF, Gafken PR, McMahon SB, Eisenman RN. Myc influences global chromatin structure. EMBO J 2006, 25:2723-2734.
69. Patel J, Du Y, Ard P, Phillips C, Carella B, Chen C-J, Rakowski C, Chatterjee C, Lieberman PM, Lane WS, Blobel GA, McMahon SB. The c-MYC oncoprotein is a substrate of the acetyltransferases hGCN5/PCAF and TIP60. Mol Cell Biol 2004, 24:10826-10834.
70. Jayapal SR, Lee KL, Ji P, Kaldis P, Lim B, Lodish HF. Down-regulation of Myc is essential for terminal erythroid maturation. J Biol Chem 2010, 285:40252-40265.
71. Lang SE, McMahon SB, Cole MD, Hearing P. E2F transcriptional activation requires TRRAP and GCN5 cofactors. J Biol Chem 2001, 276:32627-32634.
72. Love IM, Sekaric P, Shi D, Grossman SR, Androphy EJ. The histone acetyltransferase PCAF regulates p21 transcription through stress-induced acetylation of histone H3. Cell Cycle 2012, 11:2458-2466.
73. Fuks F, Milner J, Kouzarides T. BRCA2 associates with acetyltransferase activity when bound to P/CAF. Oncogene 1998, 17:2531-2534.
74. Oishi H, Kitagawa H, Wada O, Takezawa S, Tora L, Kouzu-Fujita M, Takada I, Yano T, Yanagisawa J, Kato S. An hGCN5/TRRAP histone acetyltransferase complex co-activates BRCA1 transactivation function through histone modification. J Biol Chem 2006, 281:20-26.
75. Cheung P, Tanner KG, Cheung WL, Sassone-Corsi P, Denu JM, Allis CD. Synergistic coupling of histone H3 phosphorylation and acetylation in response to epidermal growth factor stimulation. Mol Cell 2000, 5:905-915.
76. Miremadi A, Oestergaard MZ, Pharoah PDP, Caldas C. Cancer genetics of epigenetic genes. Hum Mol Genet 2007, 16 Spec No:R28-R49.
77. Ozdaǧ H, Batley SJ, Försti A, Iyer NG, Daigo Y, Boutell J, Arends MJ, Ponder BA, Kouzarides T, Caldas C. Mutation analysis of CBP and PCAF reveals rare inactivating mutations in cancer cell lines but not in primary tumours. Br J Cancer 2002, 87:1162-1165.
78. Shen H, Laird PW. Interplay between the cancer genome and epigenome. Cell 2013, 153:38-55.
79. You JS, Jones PA. Cancer genetics and epigenetics: two sides of the same coin?. Cancer Cell 2012, 22:9-20.
80. Dekker FJ, Haisma HJ. Histone acetyl transferases as emerging drug targets. Drug Discov Today 2009, 14:942-948.
81. Manzo F, Tambaro FP, Mai A, Altucci L. Histone acetyltransferase inhibitors and preclinical studies. Expert Opin Ther Pat 2009, 19:761-774.
82. Mai A, Rotili D, Tarantino D, Ornaghi P, Tosi F, Vicidomini C, Sbardella G, Nebbioso A, Miceli M, Altucci L, Filetici P. Small-molecule inhibitors of histone acetyltransferase activity: identification and biological properties. J Med Chem 2006, 49:6897-6907.
83. Furdas SD, Shekfeh S, Bissinger EM, Wagner JM, Schlimme S, Valkov V, Hendzel M, Jung M, Sippl W. Synthesis and biological testing of novel pyridoisothiazolones as histone acetyltransferase inhibitors. Bioorg Med Chem 2011, 19:3678-3689.
84. Holmlund T, Lindberg MJ, Grander D, Wallberg AE. GCN5 acetylates and regulates the stability of the oncoprotein E2A-PBX1 in acute lymphoblastic leukemia. Leukemia 2013, 27:578-585.
85. Biel M, Kretsovali A, Karatzali E, Papamatheakis J, Giannis A. Design, synthesis, and biological evaluation of a small-molecule inhibitor of the histone acetyltransferase Gcn5. Angewandte Chemie Int Ed Engl 2004, 43:3974-3976.
86. Winzeler EA, Shoemaker DD, Astromoff A, Liang H, Anderson K, Andre B, Bangham R, Benito R, Boeke JD, Bussey H, Chu AM, Connelly C, Davis K, Dietrich F, Dow SW, El Bakkoury M, Foury F, Friend SH, Gentalen E, Giaever G, Hegemann JH, Jones T, Laub M, Liao H, Liebundguth N, Lockhart DJ, Lucau-Danila A, Lussier M, M'Rabet N, Menard P, et al. Functional characterization of the S. cerevisiae genome by gene deletion and parallel analysis. Science 1999, 285:901-906.
87. Begley TJ, Rosenbach AS, Ideker T, Samson LD. Hot spots for modulating toxicity identified by genomic phenotyping and localization mapping. Mol Cell 2004, 16:117-125.
88. Yu Y, Eriksson P, Bhoite LT, Stillman DJ. Regulation of TATA-binding protein binding by the SAGA complex and the Nhp6 high-mobility group protein. Mol Cell Biol 2003, 23(6):1910-1921.
89. Alper H, Fischer C, Nevoigt E, Stephanopoulos G. Tuning genetic control through promoter engineering. Proc Natl Acad Sci U S A 2005, 102:12678-12683.
90. Lanza AM, Blazeck JJ, Crook NC, Alper HS. Linking yeast Gcn5p catalytic function and gene regulation using a quantitative, graded dominant mutant approach. PLoS One 2012, 7:e36193.
91. Begley TJ, Rosenbach AS, Ideker T, Samson LD. Damage recovery pathways in Saccharomyces cerevisiae revealed by genomic phenotyping and interactome mapping. Mol Cancer Res 2002, 1:103-112.